Werewolf Therapeutics Inc’s recently made public that its Director EVNIN LUKE unloaded Company’s shares for reported $33619.0 on Jan 12 ’26. In the deal valued at $0.57 per share,58,980 shares were sold. As a result of this transaction, EVNIN LUKE now holds 2,309,869 shares worth roughly $1.32 million.
Then, EVNIN LUKE sold 24,678 shares, generating $15,054 in total proceeds. Upon selling the shares at $0.61, the Director now owns 2,368,849 shares.
Before that, EVNIN LUKE sold 7,716 shares. Werewolf Therapeutics Inc shares valued at $4,861 were divested by the Director at a price of $0.63 per share. As a result of the transaction, EVNIN LUKE now holds 2,393,527 shares, worth roughly $1.36 million.
Wedbush downgraded its Werewolf Therapeutics Inc [HOWL] rating to a Neutral from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including JMP Securities’s analysts, who began to cover the stock in early April with a ‘”a Mkt outperform”‘ rating. Wedbush began covering HOWL with “an Outperform” recommendation on August 24, 2023.
Price Performance Review of HOWL
On Monday, Werewolf Therapeutics Inc [NASDAQ:HOWL] saw its stock fall -4.79% to $0.57. Over the last five days, the stock has lost -10.83%. Werewolf Therapeutics Inc shares have fallen nearly -60.10% since the year began. Nevertheless, the stocks have fallen -9.30% over the past one year.
How much short interest is there in Werewolf Therapeutics Inc?
A steep rise in short interest was recorded in Werewolf Therapeutics Inc stocks on 2025-12-31, growing by 1.09 million shares to a total of 2.12 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 1.03 million shares. There was a rise of 51.6%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 10, 2021 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $26 price target.
